BioCryst Pharmaceuticals announced new real-world evidence on the use of oral, once-daily ORLADEYO demonstrating that patients with hereditary angioedema in the United States experience significant reductions in healthcare resource utilization, including significant reductions in hospitalizations, emergency room visits and use of on-demand therapies, after beginning treatment with ORLADEYO. The study will be presented in a poster at the Academy of Managed Care Pharmacy Nexus 2024 national meeting, which is being held in Las Vegas from October 14-17, 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- Two Key Products Drive BioCryst (BCRX) to New Highs
- BioCryst reports inducement grants under Nasdaq listing rule
- BioCryst Begins Phase 1 Trial for Netherton Syndrome Treatment
- BioCryst begins enrollment for Phase 1 trial evaluating BCX17725
- BioCryst Secures Major US Health Department Influenza Drug Deal
Questions or Comments about the article? Write to editor@tipranks.com